• 1. Excimer–monomer switch: a reaction-based approach for selective detection of fluoride?
  Qiao Song,Angela Bamesberger,Lingyun Yang,Haley Houtwed,Haishi Cao Analyst, 2014,139, 3588-3592
• 2. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 3. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291
• 4. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 5. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Aminopyridines and derivatives

Recent Advances in the Study of 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol (CAS: 1341474-87-0)

The compound 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol (CAS: 1341474-87-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential applications in drug development and therapeutic interventions. This research brief aims to synthesize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential clinical relevance.

Recent studies have focused on the synthesis and optimization of 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol, with particular emphasis on its role as a key intermediate in the development of novel kinase inhibitors. Kinases are critical targets in the treatment of various cancers and inflammatory diseases, and the structural features of this compound make it a promising candidate for further exploration. Researchers have employed advanced computational modeling and high-throughput screening techniques to elucidate its binding affinity and selectivity towards specific kinase targets.

In addition to its potential as a kinase inhibitor, 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol has been investigated for its pharmacokinetic properties. Recent in vitro and in vivo studies have demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) profiles, suggesting its suitability for further preclinical development. Notably, the compound exhibits good solubility and stability under physiological conditions, which are critical factors for its potential use in oral formulations.

One of the most exciting developments is the application of this compound in the design of PROTACs (Proteolysis Targeting Chimeras). PROTACs are a novel class of therapeutics that degrade target proteins rather than merely inhibiting them. Preliminary data indicate that derivatives of 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol can be effectively incorporated into PROTAC molecules, enabling the targeted degradation of disease-relevant proteins. This approach holds promise for addressing drug resistance and improving therapeutic outcomes in challenging disease contexts.

Despite these promising findings, challenges remain in the optimization of 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol for clinical use. Researchers are actively working to address issues related to off-target effects and toxicity, as well as to improve the compound's bioavailability. Collaborative efforts between academic institutions and pharmaceutical companies are expected to accelerate the translation of these discoveries into viable therapeutic candidates.

In conclusion, 2-(3-amino-4-methylpyridin-2-yl)oxyethan-1-ol (CAS: 1341474-87-0) represents a versatile and promising scaffold in chemical biology and drug discovery. Its potential applications span from kinase inhibition to PROTAC development, underscoring its significance in advancing modern therapeutics. Continued research and development efforts will be crucial to fully realize its therapeutic potential and address the remaining challenges in its clinical translation.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)